Transarterial chemoembolisation-based combination therapy as a potential new standard for intermediate-stage hepatocellular carcinoma in the targeted immunotherapy era.
Combining liver cancer chemotherapy with immunotherapy works better than chemotherapy alone, but matching patients to treatment requires measuring tumor burden, blood markers, and circulating tumor DNA.
This review synthesizes landmark TACE + targeted immunotherapy trials (EMERALD-1, LEAP-012) for intermediate-stage HCC, establishing improved PFS but inconsistent OS benefit, and argues for multidimensional patient stratification incorporating tumor burden, MVI, systemic inflammation, and circulating tumor DNA. Integration of precision biomarkers into combination therapy decisions is the central recommendation.
What the study was
- Study design
- Narrative review with evidence synthesis (EMERALD-1, LEAP-012)
- Population
- Intermediate-stage HCC patients
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- BMJ Open Gastroenterology
Why it surfaced
Timely synthesis of EMERALD-1 and LEAP-012 trial data in BMJ Open Gastroenterol; HCC intermediate stage is high-burden; review limits score; OS inconsistency noted.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.